Regentis Biomaterials Ltd. (NYSE American: RGNT) announced it has received approval from the European Notified Body to manufacture GelrinC(R) using its next-generation solvent-free manufacturing process. This milestone supports the product’s planned commercial launch in Europe, according to a press release.
The company stated that the new process increases production yield by approximately 400%, producing five times more product from the same manufacturing volume. Additionally, it improves manufacturing efficiency, scalability, and occupational and environmental safety. Extensive clinical testing has validated consistent product quality and clinical performance.
GelrinC(R), which already has CE Mark approval in Europe, is a proprietary, cell-free hydrogel implant designed to regenerate cartilage through a minimally invasive 10-minute procedure. Regentis said commercialization will be supported through its expanding European Centers of Excellence, surgeon training programs, and collaborations with leading orthopedic institutions, including Humanitas Research Hospital in Milan. The company is targeting a U.S. cartilage repair market valued at approximately $3 billion.
The approval marks a significant step for Regentis as it aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S., where no off-the-shelf treatment is currently available. The enhanced manufacturing process is expected to improve supply chain capabilities and reduce production costs, potentially making the therapy more accessible to patients.
Regentis Biomaterials is a regenerative medicine company focused on developing tissue repair solutions, with its Gelrin platform technology based on synchronized, degradable hydrogel implants that regenerate damaged or diseased tissue, including inflamed cartilage and bone. GelrinC(R) is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process.
For more information, visit the company’s newsroom at https://ibn.fm/RGNT.
This development is important for the orthopedic industry as it represents a potential advancement in cartilage repair, offering an off-the-shelf solution for a large patient population. The improved manufacturing efficiency could also lead to broader adoption and lower costs, impacting patient care and healthcare systems.
